APA (7th ed.) Citation

ER, G., M, K., E, S., KJ, L., H, L., W, M., & WD, F. (2012). Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Investigational new drugs, 30(1), 90. https://doi.org/10.1007/s10637-010-9520-5

Chicago Style (17th ed.) Citation

ER, Gardner, Kelly M, Springman E, Lee KJ, Li H, Moore W, and Figg WD. "Antiangiogenic and Antitumor Activity of LP-261, a Novel Oral Tubulin Binding Agent, Alone and in Combination with Bevacizumab." Investigational New Drugs 30, no. 1 (2012): 90. https://doi.org/10.1007/s10637-010-9520-5.

MLA (9th ed.) Citation

ER, Gardner, et al. "Antiangiogenic and Antitumor Activity of LP-261, a Novel Oral Tubulin Binding Agent, Alone and in Combination with Bevacizumab." Investigational New Drugs, vol. 30, no. 1, 2012, p. 90, https://doi.org/10.1007/s10637-010-9520-5.